Investing.com - Healthcare and vaccine stocks are likely to be in the spotlight on Wednesday as Robert F. Kennedy Jr., U.S. President Donald Trump's pick to run the Department of Health and Human ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

While companies like DeepSeek may find success in certain market segments, they face an uphill battle against this massive ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

AbbVie stock trades at a forward price-to-earnings (P/E) ratio of 14.2, representing a significant discount to the S&P 500's ...

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...

Citi analyst Geoff Meacham lowered the firm’s price target on Pfizer (PFE) to $29 from $30 and keeps a Neutral rating on the shares. Ahead of ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study, published in ...